8-ANZCA-Prescription-strong-(Schedule-8)-opioid-use-and-misuse-in-Australia-submission-FINAL
PS01(PM) Statement regarding the use of opioid analgesics in patients with chronic non-cancer pain
Statement regarding the use of opioid analgesics in patients with chronic non-cancer pain
PS12(PM)BP Position Statement on the use of ketamine in the management of CNCP Background paper
2023 Lennard Travers Professorship Guide
Guidelines for applying for the 2023 Lennard Travers Professorship
ANZCA Strategic Plan 2023-2025
The ANZCA Strategic Plan 2023-2025 guides our college-wide business activity. It's the result of comprehensive consultation and engagement within the ANZCA community and beyond.
Draft clinical governance framework
College feedback on the New Zealand Health Quality and Safety Commission’s draft clinical governance framework.
2024 WA ACE Country Conference program and registration
Program and registration form for the 2024 WA ACE Country Conference, Contemplation - Learning from experience in obstetrics.
ESWG Final report June 21.docx
2023 FPM Symposium HCI Prospectus
2023 FPM Symposium HCI prospectus 23.08.22
Auditing prescribing and dispensing rates
Assessing the use of modified-release opioid analgesics within the facility is key to working towards compliance with Quality Statement 5 of the ACSQHC Clinical Care Standard (CCS1). Obtaining information and prescribing data on medication use is the first step of achieving co...